ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call Transcript

Chandan Healthcare Earnings Call Transcript: Key Takeaways

Chandan Healthcare is pivoting from pharmacy trading to a high-margin diagnostic-led strategy. The company reported healthy revenue growth but is over-relying on capital-light franchise scaling to drive future profitability.

Why this was an Alfa AlertRevenue guidance raised from 35.0% to 50.0% (+15pp).
Guidance and delivery
Revenue guidance 35.0% → 50.0% Raised by 15.0 percentage points
Management target Revenue 50.0% Next 3 years
Highlights
Revenue growth19.62% YoY growth driven by diagnostic network expansion.
MarginsStructural expansion targeting 40% EBITDA margin as pharmacy segment exits.
Demand visibilityStrong traction in Tier 2/3 markets for preventive health checkups.
Management confidenceAggressive and bullish on diagnostic transition and franchise model.

Growth

Revenue grew 19.62% YoY to ₹82.26 Cr. B2B business surged 94% while diagnostic EBITDA reached 36.57%.

Outlook

Management raised revenue growth guidance to 50% YoY for next 3 years via diagnostic expansion.

Risks

Pharmacy divestment creates short-term revenue vacuum. Heavy franchise expansion risks brand dilution and quality control issues.

Source

Earnings Call Transcript filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.

Read the document ↗

Chandan Healthcare Ltd: key numbers

Share price
₹238.00
Market cap
₹611.7 Cr
Revenue (annual)
₹276.4 Cr
Net profit (annual)
₹27.06 Cr
P/E (TTM)
22.6×Sector 54.5×
Promoter holding
47.20%-2.41% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Chandan Healthcare Ltd

All →